Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytotoxic activity of 2',2'-difluorodeoxycytidine (gemcitabine) in poorly differentiated thyroid carcinoma cells.

Thyroid : official journal of the American Thyroid Association - 1 Oct 2000

Ringel M D, Greenberg M, Chen X, Hayre N, Suzuki K, Priebat D, Saji M, Burman K D

Abstract excerpt

Poorly differentiated and anaplastic thyroid cancers are aggressive and usually fatal neoplasms, despite aggressive treatment. We performed an in vitro study to assess the activity of gemcitabine (2',2' difluorodeoxycytidine), a new fluorinated nucleoside analogue, against three poorly differentiated human thyroid carcinoma cell lines (ARO, WRO, and NPA). Each cell line was exposed to increasing concentrations of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Carcinoma

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cell Survival

Share to Deoxycytidine

Share to Dose-Response Relationship, Drug

Share to Gemcitabine

Share to Thyroid Neoplasms

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 11081253
DOI: 10.1089/thy.2000.10.865

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytotoxic activity of 2',2'-difluorodeoxycytidine (gemcitabine) in poorly differentiated thyroid carcinoma cells.PMID 11081253Read ↗

Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.Semantic proximity Read ↗

Supraadditive effect of 2 ′ ,2 ′ -difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell linesSemantic proximity Read ↗

Berberine Inhibited the Growth of Thyroid Cancer Cell Lines 8505C and TPC1Semantic proximity Read ↗

Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells.Semantic proximity Read ↗

Involvement of p53 in gemcitabine mediated cytotoxicity and radiosensitivity in breast cancer cell lines.Semantic proximity Read ↗

DFMO inhibition of neuroblastoma tumorigenesisSemantic proximity Read ↗

A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNASemantic proximity Read ↗

Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic.Semantic proximity Read ↗

Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo.Semantic proximity Read ↗

Cytotoxic activity of 2',2'-difluorodeoxycytidine, 5-aza-2'-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene.Semantic proximity Read ↗

Potential use of alexidine dihydrochloride as an apoptosis-promoting anticancer agentSemantic proximity Read ↗

Preclinical evaluation of a radiosensitizing effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.